Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 12, 2013, Pages 1740-1744

  Hahn, Theresa ^a   McCarthy, Philip L ^a   Carreras, Jeanette ^b   Zhang, Mei Jie ^b   Lazarus, Hillard M ^c   Laport, Ginna G ^d   Montoto, Silvia ^e   Hari, Parameswaran N ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Hodgkin lymphoma; Prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CHILD; COHORT ANALYSIS; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MODEL; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SCHOOL CHILD; VALIDATION PROCESS;

HODGKIN LYMPHOMA; PROGNOSIS;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887547882     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.09.018     Document Type: Article

References (33)

1. Cashen A.F., Bartlett N.L. Salvage regimens for Hodgkin lymphoma. Clin Adv Hematol Oncol 2008, 6:517-524.
2. Mendler J.H., Friedberg J.W. Salvage therapy in Hodgkin's lymphoma. Oncologist 2009, 14:425-432.
3. Colpo A., Hochberg E., Chen Y.B. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. Oncologist 2012, 17:80-90.
4. Murphy F., Sirohi B., Cunningham D. Stem cell transplantation in Hodgkin lymphoma. Expert Rev Anticancer Ther 2007, 7:297-306.
5. Moskowitz A.J., Perales M.A., Kewalramani T., et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009, 146:158-163.
6. Josting A., Rudolph C., Mapara M., et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005, 16:116-123.
7. Cooney J.P., Stiff P.J., Toor A.A., et al. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant 2003, 9:177-182.
8. Anderlini P., Saliba R., Acholonu S., et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008, 93:257-264.
9. Devetten M.P., Hari P.N., Carreras J., et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009, 15:109-117.
10. Bartlett N.L., Niedzwiecki D., Johnson J.L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, 18:1071-1079.
11. Gobbi P.G., Cavalli C., Federico M., et al. Hodgkin's disease prognosis: a directly predictive equation. Lancet 1988, 1:675-679.
12. Wagstaff J., Gregory W.M., Swindell R., et al. Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer 1988, 58:487-492.
13. Straus D.J., Gaynor J.J., Myers J., et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. JClin Oncol 1990, 8:1173-1186.
14. Proctor S.J., Taylor P., Donnan P., et al. Anumerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 1991, 27:624-629.
15. Gobbi P.G., Comelli M., Grignani G.E., et al. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica 1994, 79:241-255.
16. Lee S.M., Radford J.A., Ryder W.D., et al. Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. Br J Cancer 1997, 75:110-115.
17. Hasenclever D., Diehl V. Aprognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. NEngl J Med 1998, 339:1506-1514.
18. Stiff P.J., Unger J.M., Forman S.J., et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003, 9:529-539.
19. Sirohi B., Cunningham D., Powles R., et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1312-1319.
20. Sureda A., Constans M., Iriondo A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005, 16:625-633.
21. Hahn T., Benekli M., Wong C., et al. Aprognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 2005, 35:557-566.
22. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072.
23. Wheeler C., Eickhoff C., Elias A., et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997, 3:98-106.
24. Hahn T., McCarthy P.L., Carreras J., et al. Validation of prognostic models for progression-free survival after autologous transplant for relapsed or refractory Hodgkin lymphoma. Blood 2009, 114(Suppl.):499. abstr. 1215.
25. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616-623.
26. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. JClin Oncol 2002, 20:221-230.
27. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. NEngl J Med 2010, 363:1812-1821.
28. Chen R., Palmer J.M., Thomas S.H., et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012, 119:6379-6381.
29. Available at: Accessed July 6,2012. http://clinicaltrials.gov/ct2/show/NCT01100502.
30. Moskowitz C.H., Matasar M.J., Zelenetz A.D., et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012, 119:1665-1670.
31. Devillier R., Coso D., Castagna L., et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica 2012, 97:1073-1079.
32. Smeltzer J.P., Cashen A.F., Zhang Q., et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1646-1652.
33. Sucak G.T., Ozkurt Z.N., Suyani E., et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol 2011, 90:1329-1336.